Marker Therapeutics Inc

NASDAQ:MRKR   3:58:24 PM EDT
0.30
-0.01 (-3.22%)
Earnings Announcements

Marker Therapeutics Reports Q1 2022 Operating And Financial Results

Published: 05/13/2022 11:44 GMT
Marker Therapeutics Inc (MRKR) - Marker Therapeutics Reports Q1 2022 Operating and Financial Results.
Marker Therapeutics Inc - Plans to File Inds in Lymphoma and Pancreatic Cancer by Year End, With Clinical Trials to Be Initiated in 2023.
Marker Therapeutics Inc Qtrly Loss per Share $0.12.
Revenue is expected to be $2.5 Million
Adjusted EPS is expected to be -$0.11

Next Quarter Revenue Guidance is expected to be $0.5 Million
Next Quarter EPS Guidance is expected to be -$0.12

More details on our Analysts Page.